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Background and Purpose: We reported previously that stroke risk factors prepared the brain stem for the 
development of ischemia and hemorrhage and induced the production of tumor necrosis factor following 
an intrathecal injection of Iipopolysaccharide, a prototypic monocyte-activating stimulus. This study 
evaluates whether blood or brain cells of hypertensive rats produce more proinflammatory and 
prothrombotic mediators than do blood or brain cells of normotensive rats. 
MethotJs: Levels of tumor necrosis factor, platelet-activating factor, 6-ketoprostaglandin F1a, and 
thromboxane B2 in the cerebrospinal fluid and blood of spontaneously hypertensive and normotensive 
Wistar-Kyoto rats were monitored before and after achallenge with Iipopolysaccharide. 
Results: Little or no activity from these media tors was found in the cerebrospinal fluid or blood of 
saline-injected control animals. Intravenous administration of Iipopolysaccharide (0.001, 0.1, and 1.8 
mg/kg) produced dose-dependent increases in blood levels of all mediators in hypertensive rats. In 
normotensive rats the levels were less than in hypertensive rats and were not c1early dose-related. When 
Iipopolysaccharide was injected intracerebroventricularly, more tumor necrosis factor was measured in 
the cerebrospinal fluid than in the blood, suggesting local synthesis of this cytokine. Levels of tumor 
necrosis factor and platelet-activating factor in the cerebrospinal fluid were higher in hypertensive than 
in normotensive rats. The thromboxane A2/prostacyclin ratio was not aItered significantly between the two 
rat strains. 
Conclusions: It is suggested that the higher incidence of brain stem ischemia and hemorrhage after the 
intrathecal injection oflipopolysaccharide in hypertensive rats than in normotensive rats might be related 
to the higher levels of the two cytotoxic factors tumor necrosis factor and platelet-activating factor 
produced in response to such challenge. (Stroke 1992;23:1643-1651) 
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R isk factors for stroke increase the adhesion and emigration of mononuc1ear cells. 1 The in-creased mononuc1ear cell adhesion is re-
garded by some as the initial step in the atherosc1erotic 
process and an important contributing factor for the 
initiation of vascular injury in hypertension. 1,2 In a 
previous study, we described that several established 
risk factors for stroke (hypertension, old age, diabetes, 
genetic stroke-proneness) prepared brain stern tissue 
for a modified Shwartzman reaction, inc1uding the 
development of ischemia and hemorrhage, when chal-
lenged with a prototypic activator of monocytes, lipo-
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polysaccharide, administered as a provocative dose in-
tracisternally or intravenously.3 Recent studies from this 
laboratory further suggested that the increased fre-
quency of brain stern thrombosis and hemorrhage in rats 
with stroke risk factors after exposure to lipopolysac-
charide3 could have resulted from an exaggerated pro-
duction of proinflammatory and prothrombotic media-
tors because hypertensive rats produced more tumor 
necrosis factor (TNF-a) in the blood than normotensive 
rats when challenged with a provocative intravenous 
dose of lipopolysaccharide.4 Moreover, administration 
of lipopolysaccharide into the cerebral ventric1es of 
normotensive rats stimulated local generation of TNF-a 
into the cerebrospinal fluid. 4 The aim of the present 
study was to evaluate whether both blood and cells 
within the central nervous system of hypertensive rats 
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produce more TNF-a, eicosanoids, and platelet-activat-
ing factor (PAF) than cells of normotensive rats. We 
chose TNF-a to represent the cytokine class of media-
tors since it activates the endothelium for leukocyte 
adherence and procoagulant processes.5 Thromboxane 
B2 (TXB2), a mediator of leukocyte and platelet activa-
tion (measured relative to the stable metabolite of 
prostacyclin [PGI2]), and P AF, a mediator of hemostasis 
and inflammation,6 were chosen to reflect the level of 
activation of the hemostatic system and the potential 
risk of thrombosis. These variables were measured in 
serum and cerebrospinal fluid taken at several times 
over a dose range of lipopolysaccharide administered 
both intravenously and into the cerebral ventricles. 
Materials and Methods 
Sixteen-week-old male spontaneously hypertensive 
rats (SHR) and age-matched male normotensive 
Wistar-Kyoto rats (WKY) were purchased from Taconic 
Farms, Inc., Germantown, N.Y., and housed at 22°C 
with a 12 hour/12 hour light/dark cycle with food and 
tap water provided ad libitum. The experiments re-
ported herein were conducted according to the princi-
pies set forth in the "Guide for Care and Use of 
Laboratory Animals," Institute of Laboratory Animal 
Resources, National Research Council (DHEW publi-
cation No. NIH 85-23, 1985). 
Surgical Procedures 
The rats were anesthetized with 4% halothane in 
100% oxygen. For intravenous injections, a sterile 
PE-50 catheter was inserted into the femoral vein under 
aseptic conditions. Lipopolysaccharide from Escherichia 
coli serotype 0111:B4 (phenol extracted; Sigma Chem-
ical Co., St. Louis, Mo.) dissolved in sterile, pyrogen-
free 0.9% (wt/vol) NaCI was injected intravenously 
through the femoral vein catheter in animals receiving 
systemic injections of lipopolysaccharide. Following the 
injection, the catheter was withdrawn and the femoral 
vein ligated. For injections into the cerebral ventricles, 
the rat was placed in a stereotaxic device (David Kopf 
Instruments, Tujunga, Calif.). A midline cut was then 
made on the scalp to expose the parietooccipital bone 
area, and the muscles attached to the occiput were 
gently separated to expose the atlantooccipital mem-
brane. A stainless steel guide cannula was placed on the 
parietal skull (coordinates from bregma: anteroposte-
rior, 0.8 mm; lateral, 1.2 mm) and fixed with glue. 
Lipopolysaccharide dissolved in sterile, pyrogen-free 
0.9% NaCI was injected in a total volume of 10 pJ by 
me ans of a premeasured 30-gauge cannula (7.5 mm) 
over aperiod of 5 minutes. Two additional minutes were 
allowed for dispersal of the injected fluid before with-
drawal of the cannula. Control animals received 10 ]LI of 
sterile, pyrogen-free 0.9% NaCI through the intracere-
broventricular needle. 
In all experiments, at adesignated single time (15, 
120, or 240 minutes), the rats were anesthetized with 
halothane and mounted in a stereotaxic device. A sterile 
30-gauge ne edle attached to a sterile syringe was in-
serted into the intracisternal space through the atlan-
tooccipital membrane. Clear cerebrospinal fluid in a 
volume of 150 ]LI was withdrawn and frozen immediately 
in a sterile Eppendorf viaion dry ice. Thereafter, a 
laparotomy was performed and a sterile 23-gauge but-
terfly needle was inserted into the abdominal aorta. 
Bloos! was withdrawn through sterile syringes to allow 
simultaneous measurement of all the mediators in each 
animal. Blood sampies were collected in separate sy-
ringes as follows: 1) 4 ml blood was withdrawn into a 
cooled syringe containing 12.9 ]LM buffered sodium 
citrate, the blood was centrifuged, and the plasma was 
used for measurement of P AF; 2) 2.5 ml blood was 
withdrawn into a syringe containing 350 ]LM indometh-
acin and 100 units heparin for assay of TXB2 and 
6-ketoprostaglandin F1a (6-keto-PGF1a ); and 3) 2 ml 
blood was withdrawn into a sterile plastic tube and 
allowed to clot for assay of TNF-a. 
Tumor Necrosis Factor Assay 
The serum or cerebrospinal fluid sampies were stored 
at -20°C for 1-2 weeks until assayed using the L929 cell 
lysis bioassay as described elsewhere. 7 In brief, L929 
cells obtained from Dr. Stefanie Vogel, Department of 
Microbiology, Uniformed Services University of the 
Health Sciences, were grown in supplemented Eagle's 
minimum essential medium with 10% fetal bovine se-
rum in 150 -mI tissue culture flasks; 8 x 105 cells were 
seeded into 50 ml medium. L-cells were plated at 4x lOS 
cells/ml in a 100-]LI weIl and incubated overnight. Prior 
to the experiment, the medium was aspirated and 50 ]LI 
Eagle's minimum essential medium with 10% fetal 
bovine albumin was added to the weIl. Test sampies (50 
]LI serum or cerebrospinal fluid) underwent twofold 
serial dilutions by sequential transfer of 50 ]LI across the 
wells. In addition, 50 ]LI actinomycin D/well was added, 
to a final concentration of 0.4 ]Lg/well. Incubation after 
18 hours at 37°C was terminated by aspiration of the 
supernatants and washing with 200 ]LI normal saline/ 
weIl. After aspiration of the saline, the cells were 
stained by 50 ]LI 0.05% crystal violet in 20% ethanol for 
10 minutes. The wells were scored visually, and TNF-a 
units were calculated as the reciprocal of the highest 
dilution giving 50% lysis of a weIl. To convert to units 
per milliliter, this value was multiplied by 20. 
Platelet Activating Factor Assays 
Plasma samples. The P AF assay used for plasma 
sampies has been described in detail by Yue and 
coworkers.8 In brief, lipids were extracted from the 
sampie by the method of Bligh and Dyer9 in the 
presence of 2% acetic acid in methanol. The extracted 
sampies were sent to Dr. Tian-Li Yue, SmithKline 
Beecham Laboratories, for P AF bioassay. The extracted 
sampies were spotted onto thin-Iayer chromatography 
plates (LKSO, Whatman Inc., Clifton, N.J.). The solvent 
system used was chloroform/methanol/water (65/35/6, 
vol/vol/vol). The PAF and lyso-PAF standards were 
spotted onto the outer lanes of the thin-Iayer chroma-
tography plates between the experimental sampies for 
use as references for later identification. The plates 
were sprayed with 0.2% dichlorofluorescein in 50% 
ethanol to identify the resolved lipids. The lipid area on 
the plates with a retention factor value corresponding to 
that of the P AF standard was scraped off and extracted. 
After removal of the organic solvent by evaporation with 
N2 , the purified sampies were dissolved in 0.25% bovine 
serum albumin in saline. The P AF activity was assessed 
by platelet [3H]serotonin release as described previous-
ly.s The amount of P AF was calculated from a calibra-
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FIGURE 1. Graphs of time courses of serum 
(upper row) and cerebrospinal fluid (CSF, 
lower row) levels of tumor necrosis factor 
(TNF-a) after intracerebroventricular (ICV, 
left column) or intravenous (IV, right col-
umn) injection of lipopolysaccharide (LPS) at 
1.8 mg/kg in spontaneously hypertensive and 
normotensive Wistar-Kyoto rats. e, Hyperten-
sive rats injected with LPS; ., hypertensive rats 
injected with sterile saline; 0, normotensive 
rats injected with LPS; f'", normotensive rats 
injected with sterile saline. Values indicate 
mean ±SEM for 5 -8 rats at 15 minutes, 5-12 
rats at 120 minutes, and 4 -6 rats at 240 
minutes. Two-way analysis of variance revealed 
significant timextreatment interaction for ef 
fect of ICV LPS on CSF TNF-a concentration 
(F=8.51002, p=0.OOO85) and serum TNF-a 
concentration (F=4.56473, p=0.01358). 
Timextreatment interaction for effect of IV 
LPS on serum TNF-a concentration was sig-
nificant at F=3.22826 (p=0.04455) and on 
CSF TNF-a concentration at F=1l.81567 
(p =0. 00015). +p<0.05 0 versus f'" and e ver-
sus ., by Student-Newman-Keuls test; 
*p<0.05 e versus O. 
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tion curve of standard P AF constructed for each test. 
The specificity of [3H]serotonin release was confirmed 
by the inhibitory effect of the specific P AF antagonist 
BN50739.8 
Cerebrospinal fluid sam pies. A 100 -p.1 aliquot of cere-
brospinal fluid was used for the P AF radioimmunoassay 
using a commercial PAF radioimmunoassay kit (NEK-
062, New England NucIear-Du Pont, Boston, Mass.). 
The sensitivity of the assay was 50 pg. 
Eicosanoid Assays 
The TXBz levels were assayed by radioimmunoassay 
(New England NucIear-Du Pont). The stable PGIz 
metabolite 6-keto-PGFla was assayed directly by radio-
immunoassay using specific antibodies purchased from 
L. Levine, Brandeis University, WaItham, Mass. 
White Blood Cell Counts 
In a parallel study, 30 rats were anesthetized with 4% 
halothane in 100% oxygen. When surgical anesthesia 
was reached (usuallywithin 3-5 minutes), a laparotomy 
was performed and a sterile 23-gauge butterfly ne edle 
was inserted into the abdominal aorta. A blood sampIe 
(1 ml) was then withdrawn into a heparinized sterile 
syringe. The blood sampIes were collected in the morn-
ing .before 10 AM. The total leukocyte count of the 
freshly drawn blood was measured with an automatic 
cell counter (System 9000, Baker Instruments). The 
differential Ieukocyte counts for neutrophils, mono-
cytes, and Iymphocytes were made from a blood smear 
stained with Giemsa-Wright stain. 
Statistical Analysis 
Data in the text and figures are mean±SEM for the 
given number of rats. The dose-response and time-
response relations were analyzed by two-way analysis of 
variance (ANOVA) using the css/pc statistical package 
for microcomputers (Complete Statistical System, 
Tulsa, Oklahoma, StatSoft 1987). When ANOV A re-
vealed significant differences in the test parameters, the 
Student-Newman-Keuls test was used to analyze the 
differences between treatment groups. 
Results 
Little or no TNF-a activity was found in the cerebro-
spinal fluid or serum of control rats. Time course studies 
at the 1.8 mg/kg intravenous dose revealed a significant 
increase in the serum TNF-a level 120 minutes after 
lipopolysaccharide administration in SHR (Figure 1); at 
240 minutes the serum TNF-a level had returned to the 
control value (Figure 1). Therefore, the 120-minute 
time point was chosen for the dose-response studies. 
Intravenous administration of lipopolysaccharide at 
doses of 0.1 and 1.8 mg/kg increased the serum TNF-a 
levels in a dose-dependent manner in SHR, whereas in 
WKY the TNF-a levels were significantly less and not 
cIearly dose-related (Table 1). The cerebrospinal fluid 
levels of TNF-a were not affected by intravenous ad-
ministration of lipopolysaccharide at 120 minutes but 
were increased at 240 minutes (Figure 1). Again, the 
increase in the TNF-a concentration was greater in 
SHR than in WKY (Figure 1). 
When Iipopolysaccharide was injected intracerebro-
ventricularly, TNF-a activity in the cerebrospinal fluid 
was increased after the 1.8 mg/kg dose (Figure 1, Table 
1). The maximum level of TNF-a in the cerebrospinal 
fluid was achieved 120 minutes after intracerebroven-
tricular administration of Iipopolysaccharide, and the 
TNF-a level was still elevated at 240 minutes (Figure 1). 
After intracerebroventricular administration of lipo-
polysaccharide, in SHR TNF-a levels in the cerebrospi-
nal fluid were much higher than in the serum 
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TADLE 1. Dose-Response Effect of LPS on TNF-a Levels at 120 Minutes in Serum and CSF in SHR and Normotensive WKY 
Serum TNF-a (units/mlx 103) CSF TNF-a (units/mlx103) 
SHR WKY SHR WKY 
Treatment Mean±SEM n Mean±SEM n Mean±SEM n Mean±SEM n 
Intraeerebroventrieular administration 
Saline O±O 18 O±O 18 O±O 16 O±O 15 
LPS (mg/kg) 
0.001 1.20±0.63 8 1.28±0.61 8 3.12±1.56 8 1.71±0.39 6 
0.1 0.75±0.38 6 1.12±0.8 6 7.15±4.13 6 5.18±2.26 5 
1.8 4.55±2.06 9 2.94±0.63 10 67.58±16.75* 10 37.24±5.39 11 
Intravenous administration 
Saline 0.65±0.60 16 O±O 13 0.01±0.01 19 0.07±0.04 19 
LPS (mg/kg) 
0.001 0.11±0.04 13 0.02±0.02 14 0.16±0.04 7 0.11±0.03 8 
0.1 8.16±2.86 8 5.63±3.73 5 0.42±0.07 8 0.26±0.04 5 
1.8 15.15±4.58* 12 3.35±0.87 11 0.15±0.06 11 0.19±0.05 11 
LPS, lipopolysaeeharide; TNF-a, tumor neerosis faetor; CSF, eerebrospinal fluid; SHR, spontaneously hypertensive rats; WKY, 
Wistar-Kyoto rats. 
·p<0.05 different from WKY by Student-Newman-Keuls test. 
(67,584±16,748 units/ml compared with 4,551±2,056 
units/ml), implying that the TNF-a in the cerebrospinal 
fluid was produced locally in the brain. The increase in 
cerebrospinal fluid TNF-a activity in response to the 1.8 
mg/kg dose of lipopolysaccharide was significantly 
greater in SHR than in WKY (Figure 1, Table 1). 
Intravenously administered lipopolysaccharide 
(0.001,0.1, and 1.8 mg/kg) stimulated PAF release into 
the plasma in SHR in a dose-related manner (Table 2). 
Again, the maximum increase in P AF activity was 
reached 120 minutes after lipopolysaccharide injection 
while no significant increase was observed at 15 minutes 
or 240 minutes (Figure 2). In WKY, the increase in 
plasma P AF activity in response to intravenously ad-
ministered lipopolysaccharide was significantly less than 
in SHR. In fact, plasma P AF activity was significantly 
increased compared with the control rats only after the 
1.8 mg/kg dose of lipopolysaccharide (Figure 2, Table 
2). The cerebrospinal fluid level of P AF was elevated 
compared with the control value 15 minutes and 120 
minutes after the 1.8 mg/kg dose of lipopolysaccharide 
in SHR and after 120 minutes in WKY (Figure 2). 
When lipopolysaccharide was injected into the cere-
bral ventricles, cerebrospinal fluid P AF levels were 
increased, with the maximum reached 15 minutes after 
lipopolysaccharide administration (Figure 2). At 120 
minutes after the 1.8 mg/kg dose, cerebrospinal fluid 
levels of P AF were significantly higher in SHR than in 
WKY (Figure 2, Table 2). In SHR, plasma P AF was 
significantly increased 120 minutes after the 1.8 mg/kg 
dose of lipopolysaccharide, whereas in WKY plasma 
P AF levels were not altered (Figure 2, Table 2). 
The PGI2 and thromboxane A2 (TXA2) levels were 
measured in the plasma of SHR and WKY mentioned 
above. At 120 minutes after achallenge with intrave-
nous lipopolysaccharide at doses of 0.1 and 1.8 mg/kg, 
TADLE 2. Dose-Response Effect of LPS on PAF Levels at 120 Minutes in Plasma and CSF in SHR and Normotensive WKY 
Plasma PAF (ng/ml) CSF PAF (ng/ml) 
SHR WKY SHR WKY 
Treatment Mean±SEM n Mean±SEM n Mean±SEM n Mean±SEM n 
Intraeerebroventrieular administration 
Saline 0.27±0.01 16 0.25±0.02 13 2.60±0.38 15 1.96±0.38 9 
LPS (mg/kg) 
0.001 0.54±0.13 7 0.28±0.01 7 ND ND 
0.1 0.36±0.03 4 0.27±0.02 4 6.08±1.58 5 5.48±2.1O 4 
1.8 8.49±3.68* 10 0.91±0.22 10 5.58±0.54* 4 3.40±0.91 4 
Intravenous administration 
Saline 0.21±0.03 19 0.27±0.05 17 2.02±0.34 6 2.76±0.29 11 
LPS (mg/kg) 
0.001 0.41±0.07* 5 0.24±0.02 7 ND ND 
0.1 0.48±0.03* 7 0.36±0.03 6 1.70±0.23 4 2.13±0.12 7 
1.8 0.75±0.05* 12 0.55±0.05 16 4.36±0.75 6 4.65±0.83 8 
LPS, lipopolysaecharide; PAF, platelet-aetivating faetor; CSF, eerebrospinal fluid; SHR, spontaneously hypertensive rats; WKY, 
Wistar-Kyoto rats; ND, not determined. 
·p<0.05 different from WKY by Student-Newman-Keuls test. 
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FIGURE 2. Graphs of time courses of 
plasma (upper row) and cerebrospinal fluid 
(CSF, lower row) levels ofplatelet-activating 
factor (PAF) after intracerebroventricular 
(ICV, left column) or intravenous (IV, right 
column) injection of lipopolysaccharide 
(LPS) at 1.8 mglkg in spontaneously hyper-
tensive and normotensive Wistar-Kyoto rats. 
e, Hypertensive rats injected with LPS; ., 
hypertensive rats injected with sterile saline; 
0, normotensive rats injected with LPS; 6, 
normotensive rats injected with sterile saline. 
Values indicate mean±SEM for 5-15 rats at 
15 minutes (except four rats for IV saline), 
10-12 rats for plasma PAF and 4-8 rats for 
CSF PAF at 120 minutes, and 3-5 rats at 240 
minutes. Analysis of variance revealed signif-
icant treatment effect for ICV LPS on CSF 
PAF concentration (F=8.21636, p=0.OO598); 
timextreatment interaction was not significant 
(F=1.97685, p=0.14629). Significant timex 
treatment interaction was also found for effect 
of IV LPS on plasma PAF concentration 
(F=20.16105, p=O.OOOOl) and CSF PAF con-
centration (F=4.92271, p=0.01122). +p<0.05 
° versus 6 and e versus ., by Student-New-
man-Keuls test; *p<0.05 e versus 0. 
o 30 60 90 120 150 180 210 240 270 o 0'-""30--:6~0 -9~O~12':-0-1~50---'18-0-:2~' 0""2:-"4-0 ~270 
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TIME (min) 
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the amounts of 6-keto-PGF1a and TXB2 were signifi-
cantly increased in the plasma of both SHR and WKY 
(Table 3). After intracerebroventricular challenge, lev-
els of 6-keto-PGF1a in the plasma of SHR were in-
creased in a dose-dependent manner whereas in WKY 
no significant changes were found (Table 3). The 
plasma level of TXB2 in SHR was elevated significantly 
after the 1.8 mg/kg dose of intracerebroventricularly 
administered lipopolysaccharide. In WKY, intracere-
broventricular lipopolysaccharide had no significant ef-
fect on plasma TXB2• The level of 6-keto-PGF1a in 
plasma was significantly high er in SHR than in WKY 
after the 0.1 mg/kg and 1.8 mg/kg doses of lipopolysac-
charide, while the difference in TXB2 level was signifi-
cantly higher in SHR only after the 1.8 mg/kg dose 
(Table 3). However, at no time or dose was the TXA21 
PGI2 ratio altered. 
In parallel studies, the white blood cell counts in SHR 
and WKY ranged from 3.3x103 to 7.4x103 cells/pl The 
percentages of neutrophils, lymphocytes, and mono-
cytes in blood from 18 WKY were 19±3%, 78±3%, and 
3±1 %, respectively. The corresponding values in 20 
SHR were 28±3%, 65±3%, and 7±1%. The total white 
blood cell counts and neutrophil counts were not differ-
TABLE 3. Dose-Response Effect of LPS on Plasma Eicosanoid Levels at 120 Minutes in SHR and Normotensive WKY 
6-Ketoprostaglandin F1a (pg/ml) 
SHR WKY SHR 
Treatment Mean±SEM n Mean±SEM n Mean±SEM 
Intracerebroventricular administration 
Saline 28±8 12 15±1 12 20±3 
LPS (mg/kg) 
0.001 65±24 8 118±45 5 10±3 
0.1 89±21 * 4 10±9 4 5±1 
1.8 136±55*t 12 69±9 14 118±35*t 
Intravenous administration 
Saline 16±2 12 16±1 12 16±3 
LPS (mg/kg) 
0.001 17±6 6 13±2 7 5±3 
0.1 134±65*t 8 34±11 4 88±22t 
1.8 143±35t 12 117±27t 10 37±6 
LPS, lipopolysaccharide; SHR, spontaneously hypertensive rats; WKY, Wistar-Kyoto rats. 
*p<0.05 different from WKY by Student-Newman-Keuls test. 
tp<0.05 different from saline by Student-Newrnan-Keuls test. 
Thromboxane B2 (pg/ml) 
WKY 
n Mean±SEM n 
12 22±5 9 
7 18±7 5 
4 4±1 4 
10 38±5 10 
12 17±4 12 
6 5±1 6 
8 82±33t 4 
12 28±8 15 
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ent in SHR and WKY. However, the blood of SHR 
contained significantly fewer lymphocytes (p<0.05, Stu-
dent's two-tailed test for independent sampies) and 
significantly more monocytes (p<O.OOI, Student's two-
tailed t test) than the blood of WKY. 
Discussion 
The present study demonstrates that hypertensive 
rats produced more TNF-a in circulating blood and 
cerebrospinal fluid in response to provocative doses of 
lipopolysaccharide than normotensive rats. The exces-
sive production of TNF-a in hypertensive rats could 
prepare vessels for ischemic and inflammatory tissue 
damage via increased adhesion of monocytes and neu-
trophils on vascular endothelium and could transform 
the endothelial surface from an actively anticoagulant to 
a procoagulant state.5 The specific endothelial changes 
under the influence of TNF-a include synthesis and 
surface expression of tissue factor,lO synthesis and ex-
pression of PAF,ll release of interleukin-l (IL-l),12 
release of factor VIII/von Willebrand factor,12 and 
enhanced adhesion of monocytes and granulocytes5 via 
expression of adhesion receptor molecules.5 In addition, 
anticoagulant mechanisms such as the thrombomodu-
lin-protein C-protein S system are inhibited.1° The 
local procoagulant process could become deviation-
amplifying as more monocytes and other cells are 
recruited13,14 and the endothelium both gene rates and 
responds to IL-l and thrombin.5 The overall eflect of 
these interactions is to render the endothelial cell 
surface procoagulant, increase the adhesion of platelets 
and leukocytes, and increase local permeability. These 
disturbances could predispose to local vessel occlusion 
and circulatory impairment. 
A previous study from this laboratory suggested local 
production of TNF-a by brain tissue of normotensive 
Sprague-Dawley rats since TNF-a activity in the cere-
brospinal fluid was higher than in the blood after 
intracerebroventricular administration of lipopolysac-
charide.4 In the present study the previous findings were 
confirmed in SHR. Moreover, hypertensive rats pro-
duced more TNF-a in the cerebrospinal fluid in re-
sponse to lipopolysaccharide than normotensive rats. 
Perivascular macrophages derived from bone marrow 
could account for the production of TNF-a in the brain 
since monocytes/macrophages are the major source for 
TNF-a.5 However, several other cell types in the central 
nervous system are capable of TNF-a expression; the 
ameboid microglia share many features with macro-
phages, including production of IL-1 and TNF-a.1 5 - 17 
Astrocytes mayaiso be capable of transforming into 
macrophage-like cells18 and have been shown to release 
cytokines in vitro.16,17 The TNF-a released into the 
cerebrospinal fluid could account for the ischemic and 
hemorrhagic lesions found in the brain sterns of hyper-
tensive rats following a provocative dose of lipopolysac-
charide.3 This assumption is supported by the recent 
study that demonstrated hemorrhagic necrosis of the 
neuropil after administration of recombinant TNF-a. 19 
The release of hemostatic and proinflammatory me-
dia tors was exaggerated in rats with the stroke risk 
factor hypertension as evidenced by the increased for-
mation of P AF in the circulating blood and cerebrospi-
nal fluid after systemic and central nervous system 
administration of provocative doses of lipopolysaccha-
ride in SHR compared with normotensive WKY. Direct 
evideJlce for P AF release in stroke has been recently 
provided by studies demonstrating increased levels of 
P AF in blood from patients with ischemic stroke.20 P AF 
is a lipid media tor that induces platelet aggregation, 
increases vascular permeability, and acts as an endothe-
lial adhesion receptor for white blood cells.6 Mononu-
clear cells may act as the primary source for P AF in 
response to lipopolysaccharide,21 but PAF can be pro-
duced by many other cell types including endothelial 
cells, neutrophils, glial cells, and neurons.22-24 Interest-
ingly, TNF-a can induce P AF release from endothelial 
cell cultures.11 This may bear relevance to our results as 
the maximum levels of P AF in circulating blood were 
found 120 minutes after lipopolysaccharide administra-
tion, coinciding with the peak levels of circulating 
TNF-a. 
Plasma levels of PGI2 and TXA2 were significantly 
increased in both hypertensive and normotensive rats 
after the systemic injection of lipopolysaccharide. After 
intracerebroventricular challenge, levels of both PGI2 
and TXA2 were significantly higher in hypertensive rats' 
plasma than in that of normotensive rats. The elevation 
in eicosanoid release peaked 120 minutes after the 
challenge and might thus be related to the increased 
levels of TNF-a or P AF mentioned above. At no time or 
dose was the TXA2/PGI2 ratio altered, suggesting that 
the elevation of these eicosanoids remained balanced 
and did not contribute to an increased hemostatic 
potential. The arterial TXA2/PGI2 ratio may not reflect 
the changes in these eicosanoids at the tissue level, 
however. 
Blood pressure was not monitored in this study since 
we wanted to avoid any possibility of activation of blood 
components by surgical implantation of catheters. The 
distinct mechanisms of TNF-a and PAF release were 
not in the scope of this study and can, in our opinion, be 
dissected out only at a more defined cellular level using 
isolated cell preparations rather than an in vivo prepa-
ration. In fact, increased TNF-a release in tissues from 
hypertensive rats has been confirmed in our preliminary 
studies in which TNF-a release has been stimulated by 
in vitro incubation of carotid artery rings from hyper-
tensive and normotensive rats with lipopolysaccharide.25 
In a previous study from this laboratory,3 adepression 
of mean arterial pressure reaching a minimum of 90±8 
mm Hg in nine normotensive rats and 95 ± 11 mm Hg in 
11 SHR was recorded 1 hour after the intravenous 
injection of 1.8 mg/kg lipopolysaccharide. Thus, it could 
be conceivable that the more robust decrease in blood 
pressure in SHR compared with normotensive rats 
could contribute to the increase in plasma P AF. Con-
versely, the diflerence in the hemodynamic eflects of 
lipopolysaccharide between SHR and normotensive rats 
could also reflect the increased P AF release in hyper-
tensive animals since intravenous administration of 
P AF is known to produce a more pronounced hypoten-
sive response in SHR than in normotensive WKY.26 
Moreover, it is important to note that blood pressure 
never reached the shock level, even at the highest 
lipopolysaccharide dose, and when organs such as the 
lungs, kidneys, and sm all intestine were studied for 
histopathological signs of shock, they were found to be 
normal after lipopolysaccharide administration in both 
SHR and normotensive rats.3 In our recent (unpub-
lished) studies we found increased levels of TNF-a and 
P AF in the cerebrospinal fluid and plasma of aged 
normotensive rats after lipopolysaccharide challenge 
using a protocol similar to that used in the present 
study. 
Increased counts and activities of leukocytes, mono-
cytes, and lymphocytes in particular have been proposed 
to contribute to the risk of organ injury in SHR com-
pared with normotensive WKY.27 We could not find 
differences in the total white blood cell counts between 
these rat strains. In agreement with previous literature 
reviewed recently by Dzielak,28 we found that the 
lymphocyte counts in hypertensive rats were signifi-
cantly lower than those in normotensive rats, whereas 
the monocyte counts in hypertensive rats were elevated 
and could have contributed to the increased serum 
TNF-a levels because monocytes have been reported to 
be the primary source of TNF-a and P AF in the 
blood.21 However, the number of white blood cells, 
including monocytes and lymphocytes, in SHR and 
normotensive rats reported in our present study as weIl 
as in the study reported by Schmid-Schönbein and 
coworkers27 falls within the normal range of white blood 
cell counts in laboratory rats.29 Preliminary studies in 
our laboratory have also demonstrated that isolated 
carotid artery rings from SHR produce more TNF-a 
than rings from normotensive rats. Increased expression 
of immunoreactive TNF-a has also been reported in 
human atherosclerotic arteries.30 Therefore, it seems 
unlikely that the elevated serum levels of TNF-a in 
SHR could be entirely due to increased numbers of 
circulating monocytes. Increased levels of TNF-a and 
P AF in the cerebrospinal fluid of hypertensive rats 
compared with normotensive rats further support this 
view. 
The present data demonstrate that hypertensive rats, 
when provoked by a conventional stimulus, release 
more TNF-a and undergo a more intense activation of 
hemostatic and proinflammatory mechanisms than risk 
factor-free control rats, probably as a result of a more 
vigorous interaction of monocytes and perivascular mac-
rophages with the endothelium. These results are com-
patible with the following model: Risk factors for stroke 
are initially associated with a change in the endothe-
lium. This change would probably involve the expression 
of monocyte receptors that enable the monocytes to 
adhere to vessel walls and undergo transendothelial 
migration in both large and small vessels, leading to 
local deposits of monocyte clusters in segments of the 
blood vessels. Our recent studies using immunofluores-
cent markers for monocytes and their adhesion recep-
tors in vivo lend support to this hypothesis as the carotid 
endothelium in SHR and stroke-prone SHR but not 
normotensive WKY has been found to express the 
intercellular adhesion molecule-l and to demonstrate 
increased numbers of adherent monocytes.25 These 
monocyte clusters could then periodically signal the 
vessel endothelium via release of prothrombotic, proin-
flammatory, and chemotactic mediators such as TNF-a, 
PAF, and perhaps IL-l to convert the endothelium to a 
procoagulant state and, in effect, prepare those vessel 
segments in a manner similar to the localized ShWartz-
man paradigm.31-33 Complement activation or any stim-
ulus leading to activation of the coagulation system 
could then precipitate a localized re action of this pre-
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pared vessel segment and lead to a local thrombosis or 
hemorrhage. This could represent a general mechanism 
through wh ich risk factors for stroke operate to increase 
stroke likelihood. 
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Editorial Comment 
An increasing body of evidence serves to demonstrate 
that leukocytes during shock, ischemia, and reperfusion 
are directly involved in organ dysfunction. In the brain 
the current evidence for a cytotoxic effect by leukocytes 
during experimental ischemia or in the presence of 
arteriallesion is challenging1- S and includes preliminary 
evidence in humans.6- 8 While activation of circulating 
leukocytes may lead to complications in the microcircu-
lation of many organs, including the brain, the origin of 
the activation in selected forms of infarction and its 
exact manifestation are unresolved. Equally challenging 
questions are why persons with hypertension may be at 
risk for ischemia and hemorrhage and wh ether there 
may be a link between leukocyte entrapment in the 
microcirculation during ischemia and the conditions in 
chronic arterial hypertension. 
The above report provides evidence for transiently 
increased production of tumor necrosis factor (TNF-a) 
and platelet-activating factor (P AF) in the cerebrospi-
nal fluid and plasma of normotensive and spontaneously 
hypertensive rats after stimulation with lipopolysaccha-
ride. The enhanced production in hypertensive rats is 
detectable after intracerebroventricular and intrave-
nous lipopolysaccharide administration, especially at 
doses of 100 p,g/kg body wt and above. The authors also 
show enhanced plasma levels of eicosanoids and throm-
boxane Bz in spontaneously hypertensive rats after 
endotoxin infusion. The significance of these important 
findings lies in the fact that these chemical media tors 
stimulate inflammatory cells. P AF, thromboxane, and 
TNF-a activate neutrophils and monocytes and the 
endothelium and are prothrombotic. They could thus 
playa role in the expression of selectins on the cerebral 
vascular endothelium and the depression of endotheli-
um-derived relaxing factor release9 and may serve as a 
trigger mechanism for leukocyte infiltration, microvas-
cular obstruction, oxygen free radical production, lipid 
and protein peroxidation, thrombus formation, and 
eventual infarction. The enhanced production of these 
inflammatory mediators in hypertensive rats is an im-
portant lead to understanding the high propensity for 
organ injury in this rat strain. It is also in line with the 
poor compensatory response by spontaneously hyper-
tensive rats to a cardiovascular challenge. lO 
Leukocytes may be trapped in the microcirculation by 
a blood pressure reduction and/or cytoplasmic stiffening 
and expression of membrane adhesion proteins. Hyper-
tensive rats show signs of activation of circulating leu-
kocytes under resting conditions, and thus production of 
proinflammatory agents in response to a secondary 
stimulus may lead to a condition that favors microvas-
cular entrapment of leukocytes, even in the presence of 
normal or elevated perfusion pressures. 
This study raises several questions. Are there stimuli 
other than endotoxin administration, such as ischemia, 
that may lead to an enhanced expression of inflamma-
tory mediators in hypertensive rats? Wh at could be the 
source of the enhanced intracerebroventricular TNF-a 
and P AF production in hypertensive rats? Are resident 
cells in the brain participating, and to what degree? Is 
the enhanced production of TNF-a, thromboxane, pros-
taglandin, or P AF purely the result of endotoxin stim-
ulation or are elevated blood pressure and/or a genetic 
factor involved? In light of the fact that endotoxin per se 
stimulates neutrophils and monocytes, a high sensitivity 
of hypertensive rats to endotoxin may accompany the 
increased release of inflammatory mediators. Equally 
important is the question of whether the enhanced 
expression of thromboxane, TNF-a, or PAF may occur 
chronically in hypertensive rats, even though the pro-
duction may be localized and the levels may remain low. 
It will be interesting to monitor in the future other 
proinflammatory and prothrombotic media tors in hy-
pertensive rats and determine their effects on leukocyte 
or platelet adhesion, oxygen free radical production, 
and degranulation. This is especially interesting since 
other enzyme systems known to affect the hypertensive 
state may be affected by activated leukocytes,11,12 
Dr. Geert W. Schmid-Schönbein, Guest Editor 
Institute for Biomedical Engineering 
University of California, San Diego 
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